Veru(US:VERU)2021-09-24 12:04Financial Highlights - Veru's FY2020 net revenues were $426 million[5] - Veru's FYTD 2021 net revenues reached $456 million with a gross profit of $356 million[5] - The sexual health business generated $328 million in operating income FYTD 2021[5] - FC2 Female Condom's FY2020 net revenues were $406 million, and FYTD 2021 net revenues were $448 million[5] - Veru's cash reserves stood at $1232 million as of June 30, 2021[5] Drug Pipeline & Clinical Trials - Sabizabulin (32mg) is in Phase 3 clinical trials for metastatic castration and AR targeting agent resistant prostate cancer[10, 11] - VERU-100 is in Phase 2 clinical trials for hormone-sensitive advanced prostate cancer[10, 11] - Enobosarm is planned for a Phase 3 trial in Q3 2021 for AR+ER+HER2- metastatic breast cancer (3rd line metastatic)[10, 44] - Sabizabulin (9mg) is in Phase 3 clinical trials for hospitalized COVID-19 patients at high risk for ARDS[4, 10, 94] - TADFIN™ for BPH has a PDUFA date in December 2021[4, 100]